NSABP FB-13
NSABP FB-13
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive, HER2-Negative Primary Breast Cancer
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Thomas Julian, MD
Patient Population:
Newly diagnosed premenopausal patients with ER-positive, HER2-negative breast cancer that has not yet been treated
Target Accrual: 76 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT03628066
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive, HER2-Negative Primary Breast Cancer
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Thomas Julian, MD
Patient Population:
Newly diagnosed premenopausal patients with ER-positive, HER2-negative breast cancer that has not yet been treated
Target Accrual: 76 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT03628066